SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases

Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.

[EN] How Rodent and NHP Models Support COVID-19 Treatment Development

Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar

[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program

Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.

ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

Oncodesign: EHDEN Certified SME

EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond

With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.

Animal models for novel therapies on fibrosis and NASH